Diagnostics
Diagnostics at the Voxel Group involves the provision of highly specialised
imaging diagnostics, teleradiology services, clinical trials,
and the manufacture and sale of radiopharmaceuticals.
Diagnostics at the Voxel Group involves the provision of highly specialised
imaging diagnostics, teleradiology services, clinical trials,
and the manufacture and sale of radiopharmaceuticals.
The segment comprising the core business activities of Voxel, Scanix and Rezonans Powiśle
Diagnostics at the Voxel Group involves the provision of highly specialised diagnostic imaging services (including state-funded, commercial and private examinations), teleradiology services, clinical and pharmaceutical trials, and the manufacture and sale of radiopharmaceuticals (by Voxel).
88%
Voxel S.A.’s share in terms of sales revenue
The chart above shows the breakdown (by value) of Voxel’s sales revenue by survey type in 2022.
The main sources of revenue in the diagnostics segment come from MRI, CT and PET-CT scans
MR
Magnetic
Resonance
TK
Computed
tomography
PET-TK
Positron emission tomography
The chart below shows the number of CT, MRI and PET-CT scans carried out between 2015 and 2022 at Voxel, Rezonans Powiśle and SCANIX.
Number of tests carried out (thousands)
As part of our reimbursed services, we carry out tests on behalf of the National Health Fund
Commercial research is carried out on behalf of public hospitals and non-public healthcare providers – which have contracts with the National Health Fund – and on behalf of organisations providing healthcare services on a commercial basis.
Here is some information on the activities of the various areas within the diagnostics segment:
